Invasion is not an independent prognostic factor in high-grade glioma

Journal of Cancer Research and Therapeutics

Volumn 7, Issue 3, 2011, Pages 331-335

  Narayana, Ashwatha ^a   Perretta, Donato ^a   Kunnakkat, Saroj ^a   Gruber, Deborah ^b   Golfinos, John ^a   Parker, Erik ^a   Medabalmi, Praveen ^a   Zagzag, David ^a   Pat Eagan, R N ^b   Gruber, Michael ^b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b OVERLOOK HOSPITAL   (United States)

Author keywords

Angiogenesis; bevacizumab; high grade glioma; invasion; multifocal glioma

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE;

ADOLESCENT; ADULT; AGED; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER CONTROL; CANCER GRADING; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RELAPSE; CHILD; GLIOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; DACARBAZINE; DISEASE-FREE SURVIVAL; FEMALE; GLIOMA; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS;

EID: 81855173535     PISSN: 09731482     EISSN: 19984138     Source Type: Journal    
DOI: 10.4103/0973-1482.87039     Document Type: Article

References (29)

1. Narayana A, Recht L, Gutin PH. Central Nervous System Tumors. In: Philips TL, Hoppe R, Roach M, editors. Leibel and Philips Textbook of radiation oncology. 3 rd ed. Philadelphia: Saunders; 2010. p. 421-32.
2. Stupp R, Mason W, Bent M, Weller M, Fisher B, Taphoorn M, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96. (Pubitemid 40349501)
3. Barnard RO, Geddes JF. The incidence of multifocal cerebral gliomas. A histologic study of large hemisphere sections. Cancer 1987;60:1519-31. (Pubitemid 17141004)
4. Salvati M, Caroli E, Orlando E, Frati A, Artizzu S, Ferrante L. Multicentric glioma: Our experience in 25 patients and critical review of the literature. Neurosurg Rev 2003;26:275-9. (Pubitemid 37248222)
5. Showalter TN, Andrel J, Andrews DW, Curran Jr WJ, Daskalakis C, Werner-Wasik M. Multifocal Glioblastoma Multiforme: Prognostic Factors and Patterns of Progression. Int J Radiat Oncol Biol Phys 2007;69:820-4. (Pubitemid 47418387)
6. Djalilian HR, Shah MV, Hall WA. Radiographic incidence of multicentric malignant gliomas. Surg Neurol 1999;51:554-8. (Pubitemid 29218072)
7. Perkins GH, Schomer DF, Fuller GN, Allen PK, Maor MH. Gliomatosis cerebri: Improved outcome with radiotherapy. Int J Radiat Oncol Biol Phys 2003;56:1137-46. (Pubitemid 36794048)
8. Park S, Suh YL, Nam DH, Kim ST. Gliomatosis cerebri: Clinicopathologic study of 33 cases and comparison of mass forming and diffuse types. Clin Neuropathol 2009;28:73-82.
9. Leibel SA, Levin VA, Gutin PH. Neoplasms of the Central Nervous System. 6 th ed. In: DeVita VT, Hellman S, Rosenberg SA, editors. Philadelphia: Lippincott Williams and Wilkins; 2001.
10. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology 1980;30:907-11. (Pubitemid 10059239)
11. Chamberlain MC. Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 2010;116:3988-99.
12. Schneider BP, Sledge GW. Drug Insight: VEGF as a therapeutic target for breast cancer. Nat Clin Prac Oncol 2007;4:181-9. (Pubitemid 46358855)
13. de Groot JF, Fuller G, Kumar AJ, Piao Y, Eterovic K, Ji Y, et al. Tumor invasion after treatment of glioblastoma with bevacizumab: Radiographic and pathologic correlation in humans and mice. Neuro Oncol 2010;12:233-42.
14. Iwamoto FM, Abrey LE, Beal K, Gutin PH, Rosenblum MK, Reuter VE, et al. Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009;73:1200-6.
15. Norden A, Young G, Setayesh K, Muzikansky A, Klufas R, Ross G, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology 2008;70:779-87.
16. Macdonald D, Cascino T, Schold S, Cairncross J. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990;8:1277-80. (Pubitemid 20195640)
17. Tate MC, Aghi MK. Biology of Angiogenesis and Invasion in Glioma. Neurotherapeutics 2009;6:447-57.
18. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8:592-603.
19. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009;15:220-31.
20. Kim E, Gunther W, Yoshizato K, Meissner H, Zapf S, Nusing RM, et al. Tumor suppressor p53 inhibits transcriptional activation of invasion gene thromboxane synthase mediated by the proto-oncogenic factor ets-1. Oncogene 2003;22:7716-27. (Pubitemid 37485531)
21. Sahin A, Vercamer C, Kaminski A, Fuchs T, Florin A, Hahne JC, et al. Dominant-negative inhibition of Ets 1 suppresses tumor growth, invasion and migration in rat C6 glioma cells and reveals differentially expressed Ets 1 target genes. Int J Oncol 2009;34:377-89.
22. Krex D, Mohr B, Appelt H, Schackert HK, Schackert G. Genetic analysis of a multifocal glioblastoma multiforme: A suitable tool to gain new aspects in glioma development. Neurosurgery 2003;53:1377-84. (Pubitemid 37484867)
23. Blagosklonny MV, An WG, Romanova LY, Trepel J, Fojo T, Neckers L. p53 Inhibits Hypoxia-inducible Factor-stimulated Transcription. J Biol Chem 1998;273:11995-8. (Pubitemid 28240554)
24. Ravi R, Mookerjee B, Bhujwalla ZM, Sutter CH, Artemov D, Zeng Q, et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1a. Genes Dev 2000;14:34-44. (Pubitemid 30051577)
25. Chaichana KL, Kosztowski T, Niranjan A, Olivi A, Weingart JD, Laterra J, et al. Prognostic significance of contrast-enhancing anaplastic astrocytomas in adults. J Neurosur 2010;113:286-92.
26. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. MR Imaging Correlates of Survival in Patients with High-Grade Gliomas. AJNR Am J Neuroradiol 2005;26:2466-74.
27. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, et al. Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme. J Clin Oncol 2008;26:5610-7.
28. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, et al. Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma. J Clin Oncol 2010;28:2712-8.
29. Nowicki MO, Dmitrieva N, Stein AM, Cutter JL, Godlewski J, Saeki Y, et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro Oncol 2008;10:690-9.